Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

23 citing papers in PubMed.

1. The Impact of Killer Cell Immunoglobulin-Like Receptors and Human Leukocyte Antigen-E, Human Leukocyte Antigen-G Polymorphisms on Innate Immunity and COVID-19 Severity.Journal of immunology research · 2025
   Article
2. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.Heliyon · 2024
   Review
3. Multidimensional futuristic approaches to address the pandemics beyond COVID-19.Heliyon · 2023
   Review
4. The role of HMGB1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review.Immunology · 2023
   Review
5. Natural killer cells in COVID-19: from infection, to vaccination and therapy.Future virology · 2023
   Review
6. A patient-centric modeling framework captures recovery from SARS-CoV-2 infection.Nature immunology · 2023
   Article
7. Antigen-Specific T Cells and SARS-CoV-2 Infection: Current Approaches and Future Possibilities.International journal of molecular sciences · 2022
   Review
8. Generation of Cytotoxic T Cells and Dysfunctional CD8 T Cells in Severe COVID-19 Patients.Cells · 2022
   Article
9. NK cell dysfunction is linked with disease severity in SARS-CoV-2 patients.Cell biochemistry and function · 2022
   Review
10. A comprehensive review about immune responses and exhaustion during coronavirus disease (COVID-19).Cell communication and signaling : CCS · 2022
    Review
11. COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches.International immunopharmacology · 2022
    Review
12. Immunomodulatory Potential of Non-Classical HLA-G in Infections including COVID-19 and Parasitic Diseases.Biomolecules · 2022
    Article
13. The Pathogenetic Dilemma of Post-COVID-19 Mucormycosis in India.Aging and disease · 2022
    Article
14. Immune Responses in SARS-CoV-2, SARS-CoV, and MERS-CoV Infections: A Comparative Review.International journal of preventive medicine · 2022
    Review
15. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.Frontiers in immunology · 2022
    Review
16. Peripheral lymphocyte subset alteration in patients with COVID-19 having differential clinical manifestations.The Indian journal of medical research · 2022
    Article
17. COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us?Cytokine · 2021
    Review
18. NK Cells in Myeloproliferative Neoplasms (MPN).Cancers · 2021
    Review
19. Exploring peptide studies related to SARS-CoV to accelerate the development of novel therapeutic and prophylactic solutions against COVID-19.Journal of infection and public health · 2021
    Review
20. The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications.Viruses · 2021
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as